{"brief_title": "A Study of Viracept in HIV-Positive Women", "brief_summary": "The purpose of this study is to see if it is safe and effective to give Viracept plus stavudine (d4T) plus lamivudine (3TC) to HIV-positive women with a CD4 count <= 400 cells/mm3. This study also examines how the body handles Viracept when given with d4T and 3TC.", "condition": ["HIV Infections"], "intervention_type": ["Drug"], "intervention_name": ["Nelfinavir mesylate"], "criteria": "Inclusion Criteria Patients must have: - HIV infection. - CD4 T cell count <= 400 cells/mm3. Exclusion Criteria Prior Medication: Excluded: - Prior therapy or less than 1 month of therapy with d4T and/or 3TC. - Prior protease inhibitor therapy.", "gender": "Female", "minimum_age": "13 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Anti-HIV Agents", "mesh_term": ["HIV Infections", "Nelfinavir"], "id": "NCT00002171"}